The short version
4 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
SUPREP Bowel Prep
sodium sulfate, potassium sulfate, magnesium sulfate · SODIUM SULFATE 17.5 g/mL; POTASSIUM SULFATE 3.13 g/mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 1.6 g/mL · Solution, Concentrate · Oral · Azurity Pharmaceuticals, Inc.
NDC 24338-0175-01 · 2 BOTTLE, PLASTIC in 1 CARTON / 177.4 mL in 1 BOTTLE, PLASTIC · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 52268-0012-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$0.3393per unit
middle half $0.3374–$0.3394 · 743 plans · Apr 1, 2026
Est. net of rebatesⓘ
$0.2036–$0.2545
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
14%of plans cover it
tier 4 · prior auth 0% · step therapy 0% · qty limit 0%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for sodium sulfate, potassium sulfate, magnesium sulfate (other) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA022372
- TE code
- AA
- Approval date
- Aug 5, 2010
- Patents / exclusivity
- 0 patents, 1 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | ODE-315 | Aug 5, 2027 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of sodium sulfate, potassium sulfate, magnesium sulfate (Solution, Concentrate)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Affordable Pharmaceuticals, LLC | SODIUM SULFATE 17.5 g/mL; POTASSIUM SULFATE 3.13 g/mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 1.6 g/mL | Aug 26, 2026 | Sep 2, 2026 |
| Affordable Pharmaceuticals, LLC | SODIUM SULFATE 13.13 g/133.1mL; POTASSIUM SULFATE 2.35 g/133.1mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 1.2 g/133.1mL | Aug 26, 2026 | Sep 2, 2026 |
| Azurity Pharmaceuticals, Inc. | SODIUM SULFATE 13.13 g/133.1mL; POTASSIUM SULFATE 2.35 g/133.1mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 1.2 g/133.1mL | Aug 26, 2026 | Sep 2, 2026 |
| Azurity Pharmaceuticals, Inc. | SODIUM SULFATE 17.5 g/mL; POTASSIUM SULFATE 3.13 g/mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 1.6 g/mL | Aug 26, 2026 | Sep 2, 2026 |
| Braintree Laboratories, Inc. | SODIUM SULFATE 17.5 g/mL; POTASSIUM SULFATE 3.13 g/mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 1.6 g/mL | Aug 26, 2026 | Sep 2, 2026 |
| Braintree Laboratories, Inc. | SODIUM SULFATE 13.13 g/133.1mL; POTASSIUM SULFATE 2.35 g/133.1mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 1.2 g/133.1mL | Aug 26, 2026 | Sep 2, 2026 |
| Wilshire Pharmaceuticals, Inc. | SODIUM SULFATE 13.13 g/133.1mL; POTASSIUM SULFATE 2.35 g/133.1mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 1.2 g/133.1mL | Aug 26, 2026 | Sep 2, 2026 |
| Wilshire Pharmaceuticals, Inc. | SODIUM SULFATE 17.5 g/mL; POTASSIUM SULFATE 3.13 g/mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 1.6 g/mL | Aug 26, 2026 | Sep 2, 2026 |
| Affordable Pharmaceuticals, LLC | SODIUM SULFATE 1.6 g/mL; POTASSIUM SULFATE 3.13 g/mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 17.5 g/mL | Jul 22, 2026 | Aug 19, 2026 |
| Affordable Pharmaceuticals, LLC | SODIUM SULFATE 1.2 g/133.1mL; POTASSIUM SULFATE 2.35 g/133.1mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 13.13 g/133.1mL | Jul 22, 2026 | Aug 19, 2026 |
| Azurity Pharmaceuticals, Inc. | SODIUM SULFATE 1.6 g/mL; POTASSIUM SULFATE 3.13 g/mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 17.5 g/mL | Jul 22, 2026 | Aug 19, 2026 |
| Azurity Pharmaceuticals, Inc. | SODIUM SULFATE 1.2 g/133.1mL; POTASSIUM SULFATE 2.35 g/133.1mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 13.13 g/133.1mL | Jul 22, 2026 | Aug 19, 2026 |
| Braintree Laboratories, Inc. | SODIUM SULFATE 1.2 g/133.1mL; POTASSIUM SULFATE 2.35 g/133.1mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 13.13 g/133.1mL | Jul 22, 2026 | Aug 19, 2026 |
| Braintree Laboratories, Inc. | SODIUM SULFATE 1.6 g/mL; POTASSIUM SULFATE 3.13 g/mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 17.5 g/mL | Jul 22, 2026 | Aug 19, 2026 |
| Wilshire Pharmaceuticals, Inc. | SODIUM SULFATE 1.6 g/mL; POTASSIUM SULFATE 3.13 g/mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 17.5 g/mL | Jul 22, 2026 | Aug 19, 2026 |
| Wilshire Pharmaceuticals, Inc. | SODIUM SULFATE 1.2 g/133.1mL; POTASSIUM SULFATE 2.35 g/133.1mL; MAGNESIUM SULFATE, UNSPECIFIED FORM 13.13 g/133.1mL | Jul 22, 2026 | Aug 19, 2026 |
| Affordable Pharmaceuticals, LLC | MAGNESIUM SULFATE, UNSPECIFIED FORM 1.6 g/mL; POTASSIUM SULFATE 3.13 g/mL; SODIUM SULFATE 17.5 g/mL | Jul 15, 2026 | Jul 15, 2026 |
| Affordable Pharmaceuticals, LLC | MAGNESIUM SULFATE, UNSPECIFIED FORM 1.2 g/133.1mL; POTASSIUM SULFATE 2.35 g/133.1mL; SODIUM SULFATE 13.13 g/133.1mL | Jul 15, 2026 | Jul 15, 2026 |
| Azurity Pharmaceuticals, Inc. | MAGNESIUM SULFATE, UNSPECIFIED FORM 1.2 g/133.1mL; POTASSIUM SULFATE 2.35 g/133.1mL; SODIUM SULFATE 13.13 g/133.1mL | Jul 15, 2026 | Jul 15, 2026 |
| Azurity Pharmaceuticals, Inc. | MAGNESIUM SULFATE, UNSPECIFIED FORM 1.6 g/mL; POTASSIUM SULFATE 3.13 g/mL; SODIUM SULFATE 17.5 g/mL | Jul 15, 2026 | Jul 15, 2026 |
| Braintree Laboratories, Inc. | MAGNESIUM SULFATE, UNSPECIFIED FORM 1.6 g/mL; POTASSIUM SULFATE 3.13 g/mL; SODIUM SULFATE 17.5 g/mL | Jul 15, 2026 | Jul 15, 2026 |
| Braintree Laboratories, Inc. | MAGNESIUM SULFATE, UNSPECIFIED FORM 1.2 g/133.1mL; POTASSIUM SULFATE 2.35 g/133.1mL; SODIUM SULFATE 13.13 g/133.1mL | Jul 15, 2026 | Jul 15, 2026 |
| Wilshire Pharmaceuticals, Inc. | MAGNESIUM SULFATE, UNSPECIFIED FORM 1.2 g/133.1mL; POTASSIUM SULFATE 2.35 g/133.1mL; SODIUM SULFATE 13.13 g/133.1mL | Jul 15, 2026 | Jul 15, 2026 |
| Wilshire Pharmaceuticals, Inc. | MAGNESIUM SULFATE, UNSPECIFIED FORM 1.6 g/mL; POTASSIUM SULFATE 3.13 g/mL; SODIUM SULFATE 17.5 g/mL | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "SUPREP Bowel Prep — NDC 24338-0175-01," retrieved September 3, 2026, https://drugdashboards.com/drug/24338017501.
Free to cite with attribution — see how the data is put together.